Roderick Verhelst

Roderick Verhelst

Private Equity Investor chez
Bioqube Ventures NV
Finance
Commercial Services
Consumer Services

Profil

Roderick Verhelst is a principal at Bioqube Ventures with strong investment interest in early-stage therapeutics.
He obtained a PhD in Bioengineering at the University of Leuven and an MBA at the Solvay Brussels School of Economics & Management.
Prior to joining Bioqube Ventures, Roderick was a principal at Participatiemaatschappij Vlaanderen (PMV).
Here, he built a successful track record in life science investing and was instrumental in the formation, financing and/or exit of several start-ups, including GST (acquired by Boehringer Ingelheim), Bluebee (acquired by Illumina), Dualyx and Flamingo Therapeutics.
He served on the Board of Directors of these companies as well as Confo Therapeutics, miDiagnostics and Aelin Therapeutics.
Before his role at PMV, Roderick was an investment banker (equity research) at Degroof Petercam, where he was responsible for the life science franchise and was involved in the IPOs of argenx, Biocartis, Curetis, and Probiodrug (now Vivoryon), among others.

Postes actifs de Roderick Verhelst

SociétésPosteDébut
Private Equity Investor 01/01/2022

Anciens postes connus de Roderick Verhelst

SociétésPosteFin
Private Equity Investor 01/01/2022
Directeur/Membre du Conseil 01/01/2022
Directeur/Membre du Conseil 01/01/2022
Directeur/Membre du Conseil 01/05/2021
Directeur/Membre du Conseil 01/03/2021
Voir l'expérience en détail de Roderick Verhelst

Formation de Roderick Verhelst

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

43

Relations au 1er degré

11

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées11

Finance

Consumer Services

Finance

Finance

Consumer Services

Commercial Services

Health Technology

Health Technology

Commercial Services

Finance

Commercial Services

  1. Bourse
  2. Insiders
  3. Roderick Verhelst
DERNIÈRES HEURES | -40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !
j
:
:
PROFITEZ-EN MAINTENANT